Pharmaceutical Risk Assessment and Mitigation Act of 2024
Latest Action
Read twice and referred to the Committee on Armed Services.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Pharmaceutical Risk Assessment and Mitigation Act of 2024 is a Senate bill introduced in the 118th Congress aimed at addressing pharmaceutical risk assessment and mitigation, particularly in the context of armed forces and national security. The bill was read twice and referred to the Committee on Armed Services but ultimately failed or expired without further action. No official summary or full text is available, limiting detailed analysis of its provisions.
This bill sought to enhance pharmaceutical risk management within the armed forces but did not advance beyond committee referral and expired without enactment.
- The bill was introduced in the Senate during the 118th Congress and pertains to pharmaceutical risk assessment and mitigation.
- It falls under the policy area of Armed Forces and National Security, indicating a focus on military or defense-related pharmaceutical issues.
- The latest recorded action was referral to the Committee on Armed Services on July 8, 2024, with no further legislative progress.
['U.S. Armed Forces personnel who may be affected by pharmaceutical risk management policies', 'Department of Defense and related military health agencies involved in pharmaceutical oversight', 'Pharmaceutical manufacturers and suppliers engaged with defense contracts']
['Lack of publicly available full bill text and official summary limits transparency and understanding of specific provisions', 'Potential challenges in implementation and oversight due to absence of detailed legislative language', 'Unclear funding mechanisms and authority delegation may affect feasibility and enforcement']
The bill was introduced in the Senate and referred to the Committee on Armed Services during the 118th Congress but did not progress further. Its focus on pharmaceutical risk within the armed forces aligns with ongoing concerns about health and safety in military contexts. The failure or expiration status indicates it did not receive sufficient legislative support or prioritization.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential improvement in pharmaceutical safety protocols within military settings if enacted', 'Possible increased administrative burden on military health agencies to comply with new risk assessment requirements', 'Could influence pharmaceutical suppliers to adjust practices to meet defense-related risk mitigation standards']
The absence of an official summary and full bill text significantly limits transparency and public oversight. Monitoring the referral to the Committee on Armed Services and the bill's expiration status highlights the importance of tracking legislative progress and ensuring that stakeholders have access to complete information for informed analysis.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.